• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Finland·Healthcare·OKDBV.HE
Share

Oriola Oyj Stocks

€ 1.02Last Updated 22.04.2025

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

€ 214.68M

€ 1.02
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

03.06.2026 17:50

Finnish healthcare small cap Oriola: Losses, new targets, and hints of big changes

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Oriola Oyj, headquartered in Espoo, Finland, and established in 1907, is a leading player in the wholesale distribution of pharmaceuticals and a wide array of health and wellness products across Sweden, Finland, and international markets. Their extensive product portfolio includes vitamins, nutritional supplements, sports-specific items, wound care solutions, beauty and cosmetic goods, vaccines, and over-the-counter medications. Beyond distribution, Oriola provides a comprehensive suite of expert services. These encompass pharmaceutical logistics, specialized import of licensed medicines, personalized dose dispensing, and support for research pharmacies. The company also offers commercial data insights, clinical trial management, regulatory affairs, quality assurance, medical and scientific advisory, market access strategies, real-world evidence generation, sales support, medical translation, pharmacovigilance, medical information, and patient assistance programs, alongside general advisory services. Oriola serves a diverse client base, ranging from pharmaceutical manufacturers and pharmacies to veterinarians, hospitals, healthcare providers, specialty stores, retailers, and e-commerce businesses.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of OKDBV.HE is 1.2 and suggests 13% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendati

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.06.2026 13:01

An investment idea for all times, IPO of the year and how to keep emotions in check in the stock market

13.06.2026 03:02

Microsoft is considering spinning off Xbox into a separate company - The Information

13.06.2026 01:40

Hope for peace with Iran and SpaceX lifted spirits: stocks rose for second straight day

13.06.2026 01:05

SpaceX shares rose in value by 19% on the first day of trading. Is it worth buying them?

13.06.2026 01:04

SpaceX shares slowed before closing in first trading since record IPO

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026